Cutaneous T cell lymphoma (CTCL)

Clinical trials for Cutaneous T cell lymphoma (CTCL) explained in plain language.

Never miss a new study

Get alerted when new Cutaneous T cell lymphoma (CTCL) trials appear

Sign up with your email to follow new studies for Cutaneous T cell lymphoma (CTCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 3 Not yet recruiting 3 Not yet finished but already full! 1

New drug shows promise for tough lymphomas in early trial

Disease control Ongoing

This Phase 2 trial tests a new drug called purinostat mesylate in 50 people with relapsed or refractory peripheral T-cell lymphoma or cutaneous T-cell lymphoma. The drug is given by IV four times per 21-day cycle for up to 96 weeks. The main goal is to see if it can shrink tumors…

Matched conditions: CUTANEOUS T CELL LYMPHOMA (CTCL)

Phase 2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control

Last updated Jun 27, 2026 09:02 UTC

Cutaneous T cell lymphoma (CTCL)

Get alerted when new Cutaneous T cell lymphoma (CTCL) trials appear

New drug shows promise for tough lymphomas in early trial